97.53
price down icon0.34%   -0.33
 
loading
Novartis Ag Adr stock is traded at $97.53, with a volume of 1.47M. It is down -0.34% in the last 24 hours and down -1.58% over the past month. Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
See More
Previous Close:
$97.86
Open:
$98.37
24h Volume:
1.47M
Relative Volume:
1.21
Market Cap:
$194.99B
Revenue:
$49.94B
Net Income/Loss:
$17.60B
P/E Ratio:
11.43
EPS:
8.53
Net Cash Flow:
$12.51B
1W Performance:
-1.56%
1M Performance:
-1.58%
6M Performance:
-12.76%
1Y Performance:
-9.91%
1-Day Range:
Value
$97.45
$98.50
1-Week Range:
Value
$97.39
$99.78
52-Week Range:
Value
$92.35
$120.92

Novartis Ag Adr Stock (NVS) Company Profile

Name
Name
Novartis Ag Adr
Name
Phone
-
Name
Address
-
Name
Employee
76,057
Name
Twitter
@novartis
Name
Next Earnings Date
2024-10-29
Name
Latest SEC Filings
Name
NVS's Discussions on Twitter

Compare NVS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
97.53 194.99B 49.94B 17.60B 12.51B 8.53
Drug Manufacturers - General icon
LLY
Lilly Eli Co
725.72 689.73B 40.86B 8.37B -2.28B 9.25
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
78.69 349.44B 39.36B 13.79B 9.83B 3.086
Drug Manufacturers - General icon
JNJ
Johnson Johnson
147.03 344.63B 87.70B 14.68B 19.03B 6.05
Drug Manufacturers - General icon
ABBV
Abbvie Inc
171.56 303.17B 55.53B 5.12B 15.62B 2.88
Drug Manufacturers - General icon
MRK
Merck Co Inc
97.92 251.88B 63.17B 12.15B 14.84B 4.77

Novartis Ag Adr Stock (NVS) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-04-24 Downgrade HSBC Securities Hold → Reduce
Sep-11-24 Downgrade BofA Securities Buy → Neutral
Sep-05-24 Downgrade Goldman Buy → Neutral
Sep-03-24 Downgrade Jefferies Buy → Hold
Jul-19-24 Downgrade Deutsche Bank Buy → Hold
May-30-24 Initiated Goldman Buy
Feb-23-24 Initiated BMO Capital Markets Market Perform
Jan-23-24 Initiated Morgan Stanley Equal-Weight
Jan-16-24 Resumed UBS Buy
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Sep-25-23 Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-14-23 Initiated HSBC Securities Buy
Apr-26-23 Upgrade Deutsche Bank Hold → Buy
Mar-27-23 Upgrade Deutsche Bank Sell → Hold
Jan-26-23 Downgrade Citigroup Buy → Neutral
Dec-05-22 Upgrade Stifel Hold → Buy
Sep-15-22 Downgrade Credit Suisse Neutral → Underperform
Sep-14-22 Downgrade Berenberg Buy → Hold
May-09-22 Downgrade Wolfe Research Outperform → Peer Perform
Jan-10-22 Resumed Citigroup Buy
Dec-14-21 Downgrade Redburn Buy → Neutral
Dec-06-21 Downgrade Exane BNP Paribas Outperform → Neutral
Dec-03-21 Downgrade Bryan Garnier Buy → Neutral
Sep-20-21 Downgrade Deutsche Bank Hold → Sell
Mar-22-21 Initiated Bernstein Mkt Perform
Mar-10-21 Downgrade Argus Buy → Hold
Feb-01-21 Downgrade Cowen Outperform → Market Perform
Jan-15-21 Initiated Deutsche Bank Buy
Sep-29-20 Initiated Berenberg Buy
Sep-10-20 Upgrade UBS Neutral → Buy
Sep-01-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-15-20 Upgrade Citigroup Neutral → Buy
Mar-10-20 Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20 Downgrade Guggenheim Buy → Neutral
Apr-25-19 Upgrade Guggenheim Neutral → Buy
Apr-25-19 Upgrade Liberum Hold → Buy
Apr-10-19 Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19 Downgrade JP Morgan Neutral → Underweight
Dec-11-18 Resumed Jefferies Buy
Oct-09-18 Initiated Guggenheim Neutral
Sep-10-18 Upgrade BofA/Merrill Underperform → Buy
May-29-18 Downgrade HSBC Securities Buy → Hold
May-25-18 Upgrade Credit Suisse Underperform → Neutral
Jan-25-18 Reiterated Leerink Partners Outperform
Dec-06-17 Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17 Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17 Downgrade Credit Suisse Neutral → Underperform
Mar-09-17 Initiated Liberum Buy
View All

Novartis Ag Adr Stock (NVS) Latest News

pulisher
09:55 AM

Pain Management Therapeutics Market Is Expected To Reach Revenue Of USD 120.7 Bn By 2033, At 3.9% CAGR: Dimension Market Research. - GlobeNewswire Inc.

09:55 AM
pulisher
Jan 17, 2025

7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.

Jan 17, 2025
pulisher
Jan 10, 2025

Saudi Arabia Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 10, 2025
pulisher
Jan 09, 2025

South Korea Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 09, 2025

Thailand Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 09, 2025

The United States Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 09, 2025

The UAE Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 06, 2025

Weekly Upgrades and Downgrades - InvestorPlace

Jan 06, 2025
pulisher
Dec 19, 2024

Communiqué de presse - GlobeNewswire Inc.

Dec 19, 2024
pulisher
Dec 17, 2024

Are Investors Undervaluing Novartis (NVS) Right Now? - Yahoo Finance

Dec 17, 2024
pulisher
Dec 13, 2024

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ - Barchart

Dec 13, 2024
pulisher
Dec 13, 2024

Novartis: Time To Increase (NYSE:NVS) - Seeking Alpha

Dec 13, 2024
pulisher
Dec 09, 2024

Glaucoma Therapeutics Strategic Industry Report 2024 - GlobeNewswire Inc.

Dec 09, 2024
pulisher
Dec 05, 2024

5 high-yielding stocks that best reflect the UN’s Sustainable Development Goals - Equities News

Dec 05, 2024
pulisher
Dec 04, 2024

Novartis Canada awards more than $680,000 to community-based programs aimed at advancing health equity - Barchart

Dec 04, 2024
pulisher
Dec 04, 2024

5 High-Yielding Stocks Addressing the U.N. Sustainable Development Goals - Morningstar

Dec 04, 2024
pulisher
Nov 22, 2024

Novartis Raises Sales Outlook For Mid-Term, Acquires Kate Therapeutics - Barchart

Nov 22, 2024
pulisher
Nov 21, 2024

Addressing unmet needs for inherited neuromuscular diseases - Novartis

Nov 21, 2024
pulisher
Nov 20, 2024

Inside the Market Dominance of the Top 10 Pharma Giants - Value the Markets

Nov 20, 2024
pulisher
Nov 18, 2024

Canada Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research

Nov 18, 2024
pulisher
Nov 18, 2024

Thailand Antifungal Drugs Market Size & Outlook, 2023-2030 - Grand View Research

Nov 18, 2024
pulisher
Nov 15, 2024

MEDIA STATEMENTNovartis Canada disappointed with outcome of pCPA negotiations for metastatic castration resistant prostate cancer treatment PLUVICTO™ - Barchart

Nov 15, 2024
pulisher
Nov 06, 2024

Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance

Nov 06, 2024
pulisher
Nov 01, 2024

Our commitment to ethical and responsible use of Artificial Intelligence (AI) - Novartis

Nov 01, 2024
pulisher
Oct 29, 2024

Novartis on Pace for Largest Percent Decrease Since March 2021 — Data Talk - Morningstar

Oct 29, 2024
pulisher
Oct 29, 2024

Novartis Ag (NVS) Q3 2024 Earnings Call Transcript - Barchart

Oct 29, 2024
pulisher
Oct 29, 2024

Gene Therapy - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Chemical Biology in Biomedical Research - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Radioligand therapy: delivering now, building for the future - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Novartis at ASH - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Novartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

Novartis 2022 Financial Results - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Novartis Financial Results – Q2 2023 - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Translational medicine research at Novartis - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Novartis Financial Results – Q2 2024 - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Inclusivity - Novartis

Oct 29, 2024

Novartis Ag Adr Stock (NVS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general PFE
$26.30
price down icon 0.72%
$272.11
price up icon 0.99%
drug_manufacturers_general MRK
$97.92
price down icon 2.76%
drug_manufacturers_general SNY
$50.74
price up icon 0.00%
$91.84
price up icon 0.21%
Cap:     |  Volume (24h):